Your Fertility Appointment Today to Start Your Family Tomorrow

near

You are here

What’s New in Ovarian Aging, a Fertility Research Blog from CHR

CHR, one of the first IVF centers in the United States, has gained national and international reputation as the “fertility center of last resort” for patients with difficult cases. Located in New York City, CHR has a rigorous fertility research program that rivals those of much larger academic institutions, and this cutting-edge research effort drives the many innovations introduced into clinical infertility treatment at CHR, including DHEA supplementation for women with low ovarian reserve. CHR’s focus has been the research and treatment of diminished ovarian reserve and ovarian aging. This blog will share CHR’s exciting fertility research findings and perspectives on recent developments in fertility research.

Posts

a blog by CHR, June 7, 2012

You may have seen the media hype over an Australian study that supposedly showed that “common fertility treatments (like IVF) raise the risk of birth defects.” Although headlines of this type appear to dominate the reports on the Australian study, if you read the study itself, what the researchers found is exactly the opposite: Fertility treatments do NOT raise birth defect risk. Babies born after fertility treatments do have a slightly higher rate of birth defects, but it is because of the underlying medical issues involved in the parents’ infertility, NOT due to fertility treatments themselves.

a blog by CHR, May 9, 2012

A Belgian study found that donating eggs does not hurt egg donors’ long-term fertility prospects. This is an interesting study that confirms, one more time, what has been known for a long time. Although many women considering donating eggs do rightly wonder about any effects of egg donation to their future fertility, we have known that does not hurt a woman’s long-term fertility prospects.

a blog by CHR, April 24, 2012

A new study by the Center for Human Reproduction (CHR) casts doubt on the effectiveness of low intensity in vitro fertilization (LI-IVF) programs, also known as “mini IVF,” “natural IVF” and various other names.

a blog by CHR, April 6, 2012

A new tool developed by the Center for Human Reproduction (CHR) offers new insights into understanding ovarian reserve and may help doctors better determine a woman’s pregnancy chances with in vitro fertilization (IVF).

The tool, referred to as FSHo, is the ratio of follicle stimulating hormone levels per retrieved oocyte (egg) in an IVF cycle. Historically, when a doctor is trying to determine how well a woman’s ovaries are functioning, he or she will measure two different hormones: anti-Müllerian hormone (AMH) and follicle stimulating hormone (FSH). However, these hormones represent two different stages of the development of an egg inside the ovary, and are not necessarily very accurate predictors of whether or not an IVF cycle will result in a pregnancy for a woman with low ovarian reserve.

Add new comment

By submitting this form, you accept the Mollom privacy policy.